USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
APT THERAPEUTICS, INC.
Address:
4041 Forest Park Avenue
SAINT LOUIS, MO
Phone:
N/A
URL:
N/A
EIN:
143194771
DUNS:
192266141
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,756,140.00 8
SBIR Phase II $4,044,908.00 4

Award List:

Production of human CD39 as an antithrombotic agent

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$98,750.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Production of a human apyrase protein as an antithrombotic agent is proposed. Thrombotic vascular occlusion due to abnormal platelet aggregation can lead to many diseases, including ischemic stroke, myocardial infarction, and restenosis after angioplasty or… More

Antithrombotic Effects of Optimized Human Apyrase

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$790,435.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of the proposed work is to develop a novel antithrombotic drug that is safer and more effective than current therapies. Phase I funding for this project supported the successful development of a novel expression system to facilitate efficient production… More

Preclinical Validation of Human Apyrase in Stroke Models

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$187,435.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for acute ischemic stroke which is a leading cause of death and disability with almost no effective therapy for most patients. This enzyme strongly inhibits platelet a ctivation and aggregation with modest… More

Apyrase to Treat Ischemia/Reperfusion Injury during Lung Transplantation

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$189,572.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy to reduce ischemia/reperfusion injury which occurs in10-20% of lung transplant recipients as the consequence of unavoidable processes of procurement, preservation and restoring blood flow. This clinical… More

Human Apyrase to Disrupt Cancer Therapy

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$196,745.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for inhibition of cancer metastasis. The enzyme strongly inhibits platelet activation and aggregation without increasing bleeding risk. Using a protein informatics app roach, we have successfully engineered an… More

Adjunctive Use of Apyrase to Fibrinolytic Therapy

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$226,120.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for treatment of acute myocardial infarction. This enzyme strongly inhibits platelet activation and aggregation with modest bleeding risk. Using a protein informatics approach, we have successfully engineered… More

Apyrase to treat ischemia/reperfusion injury during lung transplantation

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$839,863.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy to prevent or reduce ischemia-reperfusion injury during lung transplantation. The enzyme strongly preserves vascular integrity and inhibits platelet activation and agg regation without increasing bleeding risk.… More

Combination Treatment of tPA and Apyrase for Stroke

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$1,107,154.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for acute ischemic stroke which is a leading cause of death and disability with almost no effective therapy for most patients. Using a protein informatics approach, we have successfully engineered a human… More

Combination Therapy of Aspirin and Apyrase for Stroke

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$287,622.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for acute ischemic stroke which is a leading cause of death and disability with almost no effective therapy for most patients. This enzyme strongly inhibits platelet a ctivation and aggregation with modest… More

Adjunctive Use of Apyrase to Fibrinolytic Therapy

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$1,307,456.00
Agency:
HHS
Principal Investigator:
Ridong Chen – 312-339-8455
Abstract:
DESCRIPTION (provided by applicant): Acute myocardial infarction is the leading cause of death in most industrialized nations. The estimated annual incidence in the US is 865,000 events, with ST-segment elevation myocardial infarction (STEMI, severe AMI)comprising an estimated 500,000 events per… More

Prevention of Vein Graft Intimal Hyperplasia with Optimized Human Apyrase

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$281,598.00
Agency:
HHS
Principal Investigator:
Ridong Chen – 312-339-8455
Abstract:
DESCRIPTION (provided by applicant): The saphenous vein is the most commonly used graft for coronary artery bypass and peripheral bypass surgery, but has poor patency. 15-20% grafts fail in the first month and approximately 25% in the first year. Early vein graft occlusion is typically due to… More

Magnetic Flow Sorter for Pancreatic Islet Isolation

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$288,298.00
Agency:
HHS
Principal Investigator:
Ridong Chen – 312-339-8455
Abstract:
DESCRIPTION (provided by applicant): Bone metastasis is common in patients with advanced breast, prostate, and lung cancers as these tumors have a remarkable ability to metastasize to bone. Two-thirds of patients with metastatic bone cancer experience severe pain which is usually described as dull… More